Clinical trials: PD1
Melanoma Stage III, Melanoma Stage IV
A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment
This is an open-label, randomized, multi-site, Phase II, interventional trial designed to evaluate the efficacy, tolerability, and safety of BNT111 + cemiplimab in anti-programmed death protein 1 (PD-1)/anti-programmed death…
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma
- Trial name
- NCT04526899
- Testing
- BNT111, Cemiplimab
- Where
- 49 sites in United States, Australia and 5 more
- Volunteers
- 184 people
- Sponsor
- BioNTech SE
Colorectal Cancer
RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer
As an established therapeutic target, HER2 is widely used in a variety of tumors, including breast cancer and gastric cancer, among which a variety of drugs, including trastuzumab, lapatinib and T-DM1, have been approved for the…
- Trial name
- DETECT (NCT05578287)
- Testing
- Anti-HER2 ADC
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Sun Yat-sen University
Solid Tumor, Bladder Cancer
LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors
This is a Phase 1/2, open-label, multi-center, single arm basket study evaluating the administration of lerapolturev ± anti programmed cell death protein 1 (PD 1)/programmed death-ligand 1 (PD L1) monoclonal antibody (mAb) (which…
- Conditions
- Solid Tumor, Bladder Cancer, Non-muscle-invasive Bladder Cancer
- Trial name
- NCT04690699
- Testing
- Lerapolturev, 5% DDM
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Istari Oncology, Inc.
Lung Neoplasm Malignant, Interstitial Lung Disease
Coorticosteroid Regimen in Patients With Anti-PD-1/PD-L1 Induced Pneumonitis
This is a prospective interventional open-label randomized trial. The patients treated with anti- PD-1 (programmed-death receptor type 1) or anti-PD-L1 (programmed-death ligand) antibodies in case of new acute onset interstitial…
- Trial name
- PROS-CONS (NCT04036721)
- Testing
- Prolonged glucocorticosteroid (prednisone) regimen, Short glucocorticosteroid (prednisone) regimen
- Where
- Poland
- Volunteers
- 85 people
- Sponsor
- National Institute for Tuberculosis and Lung Diseases, Poland
Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma
The choice of the best second-line therapy in patients with high LH R/R risk, it is a niche of knowledge not covered at the moment, especially the role of Brentuximab (BV) plus PD-1 blockade and auto-HSCT.
- Conditions
- Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Relapsed Hodgkin's Disease, Adult
- Trial name
- NCT05595447
- Testing
- Brentuximab Vedotin 50 MG [Adcetris]
- Where
- Mexico
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Hospital Regional de Alta Especialidad del Bajio
TNBC - Triple-Negative Breast Cancer, Breast Cancer
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of trilaciclib versus placebo administered prior to gemcitabine and carboplatin in patients receiving first- or…
- Trial name
- PRESERVE 2 (NCT04799249)
- Testing
- Trilaciclib, Gemcitabine, Carboplatin
- Where
- 71 sites in United States, Australia and 9 more
- Volunteers
- 194 people
- Sponsor
- G1 Therapeutics, Inc.
Nasopharyngeal Cancinoma (NPC)
Radiotherapy Omitting Prophylactic Neck Irradiation With Neoadjuvant and Adjuvant Toripalimab in Nasopharyngeal Carcinoma
This single-arm, phase 2 trial evaluates the efficacy and safety of de-escalated radiotherapy (restricted to the primary tumor, omitting prophylactic neck irradiation) combined with neoadjuvant and adjuvant toripalimab…
- Trial name
- PUPA (NCT07110558)
- Testing
- Without prophylactic neck irradiation, PD-1 antibody (Toripalimab), Cisplatin
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Sun Yat-sen University
Malignant Melanoma
Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma
This study was a mixed phase Ib/II, multi-center, open-label study of tebentafusp (IMCgp100) as a single agent, and in combination with durvalumab and/or tremelimumab, in metastatic cutaneous melanoma.
- Trial name
- NCT02535078
- Testing
- Tebentafusp (IMCgp100)
- Where
- 4 sites in United States
- Sponsor
- Immunocore Ltd
Non-small Cell Lung Cancer
Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy
This study proposes to evaluate the safety and efficacy of an anti-PD-L1 (durvalumab) agent as neoadjuvant therapy in patients diagnosed with localized NSCLC who are planned to undergo radical RT or CRT.
- Trial name
- IDEAR (NCT05267392)
- Testing
- Durvalumab, standard of care RT/RCT
- Where
- Portugal
- Volunteers
- 30 people
- Sponsor
- Instituto Portugues de Oncologia, Francisco Gentil, Porto
Colorectal Carcinoma
PD-1 Antibody Following Preoperative Chemoradiotherapy for Locally Advanced pMMR/MSS Rectal Cancer
In this open-label phase II study, patients will be scheduled for neoadjuvant treatment with PD-1 antibody following preoperative Chemoradiotherapy with capecitabine for pMMR/MSS rectal cancer staged as locally advanced…
- Trial name
- NCT04833387
- Testing
- PD-1 antibody
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Nasopharyngeal Carcinoma, Sintilimab
Sintilimab in Combination With Chemoradiotherapy in High-risk Locoregionally-advanced Nasopharyngeal Carcinoma
The program aims to enroll patients with stage high risk (AJCC 8th, T3-4N2-3M0) . Patients will receive 3 cycles of induction chemotherapy with gemcitabine and cisplatin and concurrent cisplatin-radiation plus Sintilimab, and…
- Trial name
- NCT05707819
- Testing
- Sintilimab (PD-1 Antibody)
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Cancer Hospital of Guangxi Medical University
Nasopharyngeal Carcinoma, PD-1 Inhibitors
PD-1 Inhibitors Plus Chemoradiotherapy for Metastatic Nasopharyngeal Carcinoma: an Open-label Single-arm, Phase II Trial
programmed cell death-1 (PD-1) inhibitors has been recommended as the first-line treatment for recurrent/metastatic nasopharyngeal carcinoma (R/M NPC), but progression-free survival (PFS) and overall survival (OS) was still…
- Conditions
- Nasopharyngeal Carcinoma, PD-1 Inhibitors, Chemoradiotherapy
- Trial name
- NCT05520814
- Testing
- PD-1 inhibitors, chemoradiotherapy
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sichuan Cancer Hospital and Research Institute
Solid Tumor
A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
This was an open-label, nonrandomized, Phase 1/2 study designed to determine the safety, tolerability, and efficacy of epacadostat when given in combination with pembrolizumab and 7 different chemotherapy regimens described as…
- Trial name
- NCT03085914
- Testing
- Epacadostat, Pembrolizumab, Oxaliplatin
- Where
- 16 sites in United States
- Volunteers
- 70 people
- Sponsor
- Incyte Corporation
Classical Hodgkin Lymphoma
Phase II Trial of Anti-PD-1 Antibody Treatment and Radiotherapy in Early-stage Favorable Classic Hodgkin Lymphoma
By the implementation of the anti-PD-1 antibody pembrolizumab and given its possible synergy with RT, the aim of the present trial is to develop a chemotherapy-free first-line treatment for patients with newly diagnosed…
- Trial name
- PREFer (NCT06916416)
- Testing
- Pembrolizumab
- Volunteers
- 50 people
- Sponsor
- University of Cologne
Nonsquamous Non-small Cell Lung Cancer
Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study
The purpose of this study is to assess the safety and efficacy of pemetrexed+platinum chemotherapy+pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults from mainland China with…
- Trial name
- NCT04716933
- Testing
- Pembrolizumab, Carboplatin, Cisplatin
- Where
- 19 sites in China
- Volunteers
- 201 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC)
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
The purpose of this study was to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Triple Negative Breast Cancer (TNBC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer Microsatellite Stable (MSS)
- Trial name
- NCT03549000
- Testing
- NZV930, PDR001, NIR178
- Where
- 10 sites in United States, Australia and 5 more
- Volunteers
- 127 people
- Sponsor
- Novartis Pharmaceuticals
Biliary Tract Cancer (BTC)
A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC
Biliary tract cancer (BTC) is a rare heterogeneous collection of malignancies arising within the biliary tract, characterized by innate chemoresistance and abysmal prognosis.
- Trial name
- NCT04004234
- Testing
- Manganese Chloride, nab-paclitaxel, Gemcitabine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese PLA General Hospital
Intrahepatic Cholangiocarcinoma (Icc)
Efficacy and Safety of HAIC Combined With Lenvatinib and PD-1 Inhibitors for Advanced Intrahepatic Cholangiocarcinoma
Intrahepatic Cholangiocarcinoma (ICC), the second most prevalent primary malignant liver neoplasm, features highly aggressive biological behavior and dismal prognosis.
- Trial name
- LPHAIC for ICC (NCT07646717)
- Testing
- hepatic arterial infusion chemotherapy (Irinotecan liposome plus 5-FU/LV) combined with lenvatinib and PD-1 inhibitors
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Melanoma (Skin Cancer)
Exploratory Study With Parallel Controls on the Safety and Efficacy of Neoadjuvant Low Branched-Chain Amino Acid Diet in Combination With Anti-PD-1 Monoclonal Antibody for Stage III Melanoma
1. Primary Objective: To evaluate the safety of a low branched-chain amino acid diet (60% of the normal dietary BCAA content) combined with anti-PD-1 monoclonal antibody as neoadjuvant therapy in patients with stage III melanoma…
- Trial name
- NCT07586891
- Testing
- Low Branched-Chain Amino Acid Diet
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Xijing Hospital
Ineligible Or Refused Transplant Patients With Classical Hodgkin Lymphoma
Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.
The prognosis for patients with relapsed/refractory classical Hodgkin lymphoma (cHL) who refuse or are ineligible for transplant is poor.
- Trial name
- NCT06563778
- Testing
- Chidamide; Decitabine; Anti-PD-1 Antibody, Brentuximab Vedotin+ Bendamustine+Anti-PD-1 antibody
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Chinese PLA General Hospital